Cencora Inc. (COR)
Official siteHEALTHCARE • MEDICAL DISTRIBUTION • NYSE
Market Cap: $68.51B
Last updated: Nov 17, 2026 at 11:05 AM ET
Cencora Inc. (COR) Earnings: Report Dates and Results
Cencora (COR) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Cencora reported EPS of $4.66, above the $4.56 estimate. It beat the EPS estimate in each of the last 19 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
COR has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 13.2% above the $4.08 reported for the quarter ended Dec 31, 2025.
COR Earnings Call
The latest COR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, COR beat 38, missed 1 and matched 1. The widest gap in the table came in the quarter ended Jun 30, 2020, when EPS landed 16.35% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $4.66 | $4.56 | $4.53 - $4.62 | +2.19% | Beat | +21.4% | 9 | 1 up, 0 down | Nov 4, 2026 | N/A |
| Jun 30, 2026 | $4.48 | $4.37 | $4.29 - $4.43 | +2.52% | Beat | +12.0% | 12 | 1 up, 1 down | Aug 5, 2026 | $84.75B |
| Mar 31, 2026 | $4.75 | $4.73 | $3.57 - $4.91 | +0.42% | Beat | +7.5% | 14 | 0 up, 2 down | May 6, 2026 | $78.36B |
| Dec 31, 2025 | $4.08 | $4.04 | $3.89 - $4.36 | +0.99% | Beat | +9.4% | 14 | 3 up, 1 down | Feb 4, 2026 | $85.93B |
| Sep 30, 2025 | $3.84 | $3.79 | $3.71 - $3.84 | +1.32% | Beat | +15.0% | 15 | 1 up, 4 down | Nov 5, 2025 | $83.73B |
| Jun 30, 2025 | $4.00 | $3.84 | $3.65 - $3.98 | +4.17% | Beat | +19.8% | 13 | 3 up, 0 down | Aug 6, 2025 | $80.66B |
| Mar 31, 2025 | $4.42 | $4.10 | $3.99 - $4.20 | +7.80% | Beat | +16.3% | 12 | 5 up, 0 down | May 7, 2025 | $75.45B |
| Dec 31, 2024 | $3.73 | $3.52 | $3.42 - $3.61 | +5.97% | Beat | +13.7% | 13 | 6 up, 3 down | Feb 5, 2025 | $81.49B |
| Sep 30, 2024 | $3.34 | $3.22 | $3.18 - $3.28 | +3.73% | Beat | +16.8% | 15 | 5 up, 0 down | Nov 6, 2024 | $79.05B |
| Jun 30, 2024 | $3.34 | $3.22 | $3.11 - $3.32 | +3.73% | Beat | +14.4% | 14 | 3 up, 1 down | Jul 31, 2024 | $74.24B |
| Mar 31, 2024 | $3.80 | $3.69 | N/A | +2.98% | Beat | +8.6% | N/A | N/A | May 1, 2024 | $68.41B |
| Dec 31, 2023 | $3.28 | $2.89 | $2.80 - $2.92 | +13.49% | Beat | +21.0% | 8 | 2 up, 1 down | Jan 31, 2024 | $72.25B |
| Sep 30, 2023 | $2.86 | $2.81 | $2.77 - $2.83 | +1.78% | Beat | +10.0% | 11 | 2 up, 1 down | Nov 2, 2023 | $68.92B |
| Jun 30, 2023 | $2.92 | $2.83 | N/A | +3.18% | Beat | +11.5% | N/A | N/A | Aug 2, 2023 | $66.95B |
| Mar 31, 2023 | $3.50 | $3.30 | N/A | +6.06% | Beat | +8.7% | N/A | N/A | May 2, 2023 | $63.46B |
| Dec 31, 2022 | $2.71 | $2.63 | N/A | +3.04% | Beat | +5.0% | N/A | N/A | Feb 1, 2023 | $62.85B |
| Sep 30, 2022 | $2.60 | $2.57 | N/A | +1.17% | Beat | +8.8% | N/A | N/A | Nov 3, 2022 | $61.17B |
| Jun 30, 2022 | $2.62 | $2.56 | N/A | +2.34% | Beat | +21.3% | N/A | N/A | Aug 3, 2022 | $60.06B |
| Mar 31, 2022 | $3.22 | $2.92 | N/A | +10.27% | Beat | +27.3% | N/A | N/A | May 4, 2022 | $57.72B |
| Dec 31, 2021 | $2.58 | $2.58 | N/A | 0.00% | In line | +18.3% | N/A | N/A | Feb 2, 2022 | $59.63B |
| Sep 30, 2021 | $2.39 | $2.36 | N/A | +1.27% | Beat | +26.5% | N/A | N/A | Nov 4, 2021 | $58.91B |
| Jun 30, 2021 | $2.16 | $2.04 | N/A | +5.88% | Beat | +16.8% | N/A | N/A | Aug 4, 2021 | $53.41B |
| Mar 31, 2021 | $2.53 | $2.46 | N/A | +2.85% | Beat | +5.4% | N/A | N/A | May 5, 2021 | $49.15B |
| Dec 31, 2020 | $2.18 | $1.94 | N/A | +12.37% | Beat | +23.9% | N/A | N/A | Feb 4, 2021 | $52.52B |
| Sep 30, 2020 | $1.89 | $1.87 | N/A | +1.07% | Beat | +17.4% | N/A | N/A | Nov 5, 2020 | $49.24B |
| Jun 30, 2020 | $1.85 | $1.59 | N/A | +16.35% | Beat | +5.1% | N/A | N/A | Aug 5, 2020 | $45.37B |
| Mar 31, 2020 | $2.40 | $2.27 | N/A | +5.73% | Beat | +13.7% | N/A | N/A | May 7, 2020 | $47.42B |
| Dec 31, 2019 | $1.76 | $1.67 | N/A | +5.39% | Beat | +10.0% | N/A | N/A | Jan 30, 2020 | $47.86B |
| Sep 30, 2019 | $1.61 | $1.58 | N/A | +1.90% | Beat | +11.0% | N/A | N/A | Nov 7, 2019 | $45.64B |
| Jun 30, 2019 | $1.76 | $1.62 | N/A | +8.64% | Beat | +14.3% | N/A | N/A | Aug 1, 2019 | $45.24B |
| Mar 31, 2019 | $2.11 | $1.96 | N/A | +7.65% | Beat | +8.8% | N/A | N/A | May 2, 2019 | $43.32B |
| Dec 31, 2018 | $1.60 | $1.51 | N/A | +5.96% | Beat | +3.2% | N/A | N/A | Jan 31, 2019 | $45.39B |
| Sep 30, 2018 | $1.45 | $1.46 | N/A | -0.68% | Miss | +9.0% | N/A | N/A | Nov 6, 2018 | $43.30B |
| Jun 30, 2018 | $1.54 | $1.45 | N/A | +6.21% | Beat | +7.7% | N/A | N/A | Aug 2, 2018 | $43.14B |
| Mar 31, 2018 | $1.94 | $1.82 | N/A | +6.59% | Beat | +9.6% | N/A | N/A | May 2, 2018 | $41.03B |
| Dec 31, 2017 | $1.55 | $1.35 | N/A | +14.81% | Beat | +14.0% | N/A | N/A | Feb 6, 2018 | $40.47B |
| Sep 30, 2017 | $1.33 | $1.32 | N/A | +0.76% | Beat | +2.3% | N/A | N/A | Nov 2, 2017 | $39.12B |
| Jun 30, 2017 | $1.43 | $1.37 | N/A | +4.38% | Beat | +4.4% | N/A | N/A | Aug 3, 2017 | $38.71B |
| Mar 31, 2017 | $1.77 | $1.68 | N/A | +5.36% | Beat | +5.4% | N/A | N/A | May 4, 2017 | $37.15B |
| Dec 31, 2016 | $1.36 | $1.23 | N/A | +10.57% | Beat | +7.1% | N/A | N/A | Jan 31, 2017 | $38.17B |
Annual EPS
EPS for the fiscal year ended Sep 30, 2026 was $17.97, up 12.4% from the year before. It was $5.89 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | $17.97 | +12.4% |
| Sep 30, 2025 | $15.99 | +16.2% |
| Sep 30, 2024 | $13.76 | +14.8% |
| Sep 30, 2023 | $11.99 | +8.8% |
| Sep 30, 2022 | $11.02 | +19.0% |
| Sep 30, 2021 | $9.26 | +17.2% |
| Sep 30, 2020 | $7.90 | +11.6% |
| Sep 30, 2019 | $7.08 | +9.3% |
| Sep 30, 2018 | $6.48 | +10.0% |
| Sep 30, 2017 | $5.89 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,600 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,587 | 16 | |
| 2026Q2 | Jun 30, 2026 | 7,333 | 15 | |
| 2026Q1 | Mar 31, 2026 | 8,629 | 17 | |
| 2025Q4 | Dec 31, 2025 | 8,484 | 15 | |
| 2025Q3 | Sep 30, 2025 | 6,897 | 16 | |
| 2025Q2 | Jun 30, 2025 | 7,354 | 15 | |
| 2025Q1 | Mar 31, 2025 | 7,782 | 17 | |
| 2024Q4 | Dec 31, 2024 | 2,664 | 15 |
2026Q3 Earnings Call
Opening remarks
Bennett Murphy Senior Vice President, Investor Relations and Enterprise Productivity Good morning, good afternoon, and thank you all for joining us for this conference call to discuss Cencora's fiscal 2026 third quarter results. I am Bennett Murphy, Senior Vice President, Investor Relations and Enterprise Productivity. Joining me today are Bob Mauch, President and CEO; and Eva Boratto, Executive Vice President and CFO. On today's call, we will be discussing non-GAAP financial measures. Reconciliations of these measures to GAAP are provided within today's press release, which is available on our website at investors.cencora.com. We've also posted a slide presentation to accompany today's press release on our investor website. During this conference call, we will discuss forward-looking statements about our business and financial expectations on an adjusted non-GAAP basis, including, but not limited to, EPS, operating income and income taxes. Forward-looking statements are based on management's current expectations and are subject to uncertainty and change. For a discussion of key risks and assumptions, we refer you to today's press release and our SEC filings, including our most recent 10-Q. Cencora assumes no obligation to update any forward-looking statements, and this call cannot be rebroadcast without the permission of the company. You have the opportunity to ask questions after today's remarks by management. We ask that you limit your questions to one per participant in order for us to get to as many as possible. With that, I'll turn the call over to Bob.
Robert Mauch President and CEO Thank you, Bennett. Hi, everyone, and thank you for joining Cencora's fiscal 2026 Third Quarter Earnings Call. To start, I'd like to thank our Cencora team members for their continued commitment to providing valuable solutions for our customers. In our third quarter, we delivered strong results driven by execution across Cencora and investments to advance our specialty positioning and our pharmaceutical-centric strategy. Our business performance drove double-digit adjusted operating income growth and, supported by $1 billion of opportunistic share repurchases, we achieved 12% EPS growth in the quarter. We're pleased to be raising our fiscal 2026 EPS guidance, reflecting our confidence in our continued execution and the strength of our portfolio as we close out the fiscal year. I'm very happy Eva Boratto has joined us as Chief Financial Officer. She will provide details on our performance and continued confidence in our short- and long-term expectations. During my remarks today, I'll highlight how our strategy enables us to deliver on our growth priorities. First, our differentiated specialty pharmaceutical platform uniquely positions us to support innovation and patient care across our footprint. Second, through our digital transformation, we are modernizing how we operate and serve our partners.
Frequently Asked Questions About COR
When is Cencora's next earnings date?
Cencora's next earnings report is expected for Feb 2, 2027.
Did COR beat earnings estimates last quarter?
Yes. Cencora reported EPS of $4.66 for the quarter ended Sep 30, 2026, above the $4.56 estimate, a 2.19% surprise.
What EPS do analysts expect from COR next quarter?
The consensus EPS estimate for Cencora for the quarter ending Dec 31, 2026 is $4.62 from 6 analysts, with estimates from $4.53 to $4.94.
How often does COR beat earnings estimates?
Cencora beat the EPS estimate in each of the last 19 quarters, with an average surprise of +4.06%.
COR pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts